Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Acid ceramidase confers radioresistance to glioblastoma cells. Oncol Rep 2017 Oct;38(4):1932-1940 PMID: 28765947

Abstract

Glioblastoma multiforme (GBM) is the most common primary, intracranial malignancy of the central nervous system. The standard treatment protocol, which involves surgical resection, and concurrent radiation with adjuvant temozolomide (TMZ), still imparts a grim prognosis. Ultimately, all GBMs exhibit recurrence or progression, developing resistance to standard treatment. This study demonstrates that GBMs acquire resistance to radiation via upregulation of acid ceramidase (ASAH1) and sphingosine‑1-phosphate (Sph-1P). Moreover, inhibition of ASAH1 and Sph-1P, either with humanized monoclonal antibodies, small molecule drugs (i.e. carmofur), or a combination of both, led to suppression of GBM cell growth. These results suggest that ASAH1 and Sph-1P may be excellent targets for the treatment of new GBMs and recurrent GBMs, especially since the latter overexpresses ASAH1.

Author List

Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP

Authors

Jennifer M. Connelly MD Associate Professor in the Neurology department at Medical College of Wisconsin
Wade M. Mueller MD Professor in the Neurosurgery department at Medical College of Wisconsin
Scott D. Rand MD, PhD Professor in the Radiology department at Medical College of Wisconsin
Kathleen M. Schmainda PhD Professor in the Radiology department at Medical College of Wisconsin



View this publication's entry at the Pubmed website PMID: 28765947
jenkins-FCD Prod-130 96200611f8481f0aa4f84230b11dd74d063847a3